Phase One Clinical Trial: Cabozantinib

             On Thursday, October 23, David started a Phase One clinical trial of cabozantinib. He takes the pill at home each morning and goes to MGH twice a week to check his blood counts.

            For the first two weeks, ending two days ago, he was allowed to take hydroxyurea to lower the white blood count while we wait to see if the cabozantinib will attack the blasts.

Date	White Blood Cell Count	Percentage Blasts
6-Oct-14	2.2	2.60%
10-Oct-14	2.7	8%
15-Oct-14	3	9.20%
23-Oct-14	15.7	47%
24-Oct-14	14.9	53%
26-Oct-14	15.5	65%
30-Oct-14	8.81	55%
2-Nov-14	6.68	33%
5-Nov-14	4.8	39%

            The lower blast percentage is good news, however, it is too early to know whether the cabozantinib is having any effect.

            Last Sunday, Jim, David, and I drove to the Bronx to visit Peter, Xiomara, and Andrew. Monday evening we (sans Andrew) attended R’els first concert with the Oratorio Society of New York. They performed Haydn’s The Creation in Carnegie Hall. It was superb.